Emergent BioSolutions Inc. (EBS) Stock

Emergent BioSolutions Inc. (EBS) is a Healthcare stock trading at $5.08 (as of 2026-08-21), with a market capitalization of $262.37M and a trailing P/E of 2.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response products for public health threats, including chemical, biological, radiological, nuclear, and explosive events, as well as emerging infectious diseases and related emergency care needs in the United States. Its portfolio includes vaccines, antitoxins and immunoglobulin therapies, antibody treatments, decontamination products, and some emergency treatments and travel-related vaccines.

Understand Emergent BioSolutions Inc.: how it makes money

Emergent BioSolutions develops and supplies preparedness and response solutions for public health threats, selling medical countermeasures such as vaccines and treatments, and also earns revenue from contract development and manufacturing organization services.

The company’s profit model is a mix of (1) medical countermeasures products and (2) contract development and manufacturing organization services, so near-term results depend on new US government contract activity for medical countermeasures and new CDMO business wins.

Business quality (Weak): Business and operating focus are clear (medical countermeasures plus CDMO), but the provided segment revenue candidates are not mutually exclusive, so a clean segment breakdown to match total revenue is not possible from the given facts.

Bull case

Two revenue drivers, products and CDMO services: Emergent provides medical countermeasures (including vaccines and treatments) and also offers contract development and manufacturing organization services.
Government-linked demand and continued pipeline tracking: The company tracks new United States government contract value for medical countermeasures, and also tracks CDMO new business wins.

Bear case

Funding and award timing risk: If new United States government contracts (medical countermeasures) are delayed or reduced, the products side can face revenue pressure.
CDMO conversion variability: Because CDMO performance is tied to new business wins, slower conversion from wins and pipeline can affect services revenue.
Low operating buffer: The latest quarter shows an operating margin of 6.7%, which can leave less room to absorb cost or execution swings.

Valuation — source: SEC EDGAR (first-party)
Price	$5.08
Market Cap	$262.37M
P/E Ratio	2.3
EV / EBITDA	3.3
Price / Book	0.50
Price / Sales	0.35
FCF Yield	46.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$742.90M
Net Margin	7.1%
Revenue Growth (YoY)	-28.8%
EPS Growth (YoY)	-127.2%
FCF Growth (YoY)	338.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.33 (distress)
Piotroski F-Score	8/9 (strong)

Valuation vs Sector & Industry
Stock P/E	2.3
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2
vs Sector	-89.4%
vs Industry	-86.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock Fund Advisors ($87.47M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Joseph C. Papa Jr.
Employees	900
Country	US
IPO Date	2006-11-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.